Fortress Biotech, Inc. .header-logo-0 .cls-1{ fill: #4e5363; } header-logo Home About Programs News & Media Investors Contact Careers Accessibility Statement An Innovative Biopharmaceutical Company Building a Diversified Pipeline of Revenue-Generating Pharmaceutical Products and Development-Stage Product Candidates At Fortress Biotech, Inc., we leverage our extensive biopharmaceutical business and comprehensive drug development expertise to build a pipeline of both commercial-stage products and development-stage product candidates, as well as to advance our products and pipeline as efficiently as possible with our partners. ABOUT US Go to Content A Robust, Late-Stage Product Pipeline Over 25 Programs in Development We are dedicated to developing novel therapies and solutions for a wide variety of patients in need. Our pipeline of more than 25 programs developed across our partner companies spans several large-market therapeutic areas and includes multiple late-stage product candidates. Diverse Therapeutic Areas Oncology / Hematology Gene Therapy Neurology Pain Management Rare Diseases Infectious Diseases Dermatology CNS Disorders Rheumatology Our Current Programs1 Commercial Late Stage Product Candidates Early Stage Product Candidates Preclinical LATE STAGE PRODUCT CANDIDATES Candidate Indication Partnership; Royalty2 IV Tramadol Post-Surgical Acute Pain 23% Avenue; 10-20% CVR Royalty on Gross Profits NDA Filed Phase in progress CUTX-101 Menkes Disease 70% Cyprium; 4.5% Royalty Phase 3 Phase in progress MB-107 Newly Diagnosed X-Linked Severe Combined Immunodeficiency (XSCID) 17% Mustang; 4.5% Royalty Phase 2 Phase in progress MB-207 Previously Transplanted X-Linked Severe Combined Immunodeficiency (XSCID) 17% Mustang; 4.5% Royalty Phase 2 Phase in progress Cosibelimab 3 cSCC 19% Checkpoint; 4.5% Royalty Phase 1 Phase in progress Olafertinib Frontline NSCLC with EGFR Mutations 19% Checkpoint; 4.5% Royalty Phase 1 Phase in progress CAEL-101 4 AL Amyloidosis 42% Caelum Phase 3 Phase in progress DFD-29 5 Rosacea 93% Journey Medical Corporation Phase 2 Phase in progress Triplex Cytomegalovirus (CMV) 82% Helocyte; 4.5% Royalty Phase 2 Phase in progress CEVA 101 Pediatric Traumatic Brain Injury (TBI) 78% Cellvation; 4.5% Royalty Phase 2 Phase in progress CEVA 101 Adult Traumatic Brain Injury (TBI) 78% Cellvation; 4.5% Royalty Phase 2 Phase in progress Includes product candidates in development at Fortress, its majority-owned and majority-controlled partner companies and entities in which it holds minority ownership positions. Column reflects approximate percentage ownership in Fortress partner company and corresponding direct product sales royalties owed to Fortress as of 9/30/2021 P1 Registration enabling expansion cohorts ongoing; potential to support 1 or more BLA filings AstraZeneca’s Alexion acquired Caelum Biosciences on 10/5/2021 for up to $500 million, including $150 million upfront and up to $350 million in future contingent milestone payments. FBIO received ~$64 million of such upfront amount and is eligible to receive ~43% of the proceeds from all future milestone payments. Fortress currently owns 93% of Journey Medical Corporation on an outstanding share basis, 62% on a fully-diluted basis as of 9/30/2021. World-Class Partners We have established relationships with some of the world's leading academic research institutions and biopharmaceutical companies. PARTNER WITH US Previous slide Next slide •••••••• Alexion Pharmaceuticals, Inc. In January 2019, Caelum Biosciences, Inc., a Fortress Biotech partner company, signed an agreement with Alexion Pharmaceuticals, Inc. to advance the development of CAEL-101 for light chain (AL) amyloidosis. The collaboration leverages Alexion’s expertise in rare disease antibody development and commercial franchise in hematology. Latest News VIEW ALL NEWS Nov 17, 2021 Avenue Therapeutics Announces Exercise and Closing of Underwriter’s Over-Allotment Option Nov 16, 2021 Journey Medical Corporation Announces Closing of Initial Public Offering VIEW PRESS RELEASE Nov 15, 2021 Fortress Biotech Reports Record Third Quarter 2021 Financial Results and Recent Corporate Highlights VIEW PRESS RELEASE Nov 12, 2021 Avenue Therapeutics Announces Closing of Public Offering of Common Stock VIEW PRESS RELEASE Email Alerts Stay informed and receive company updates straight to your inbox. SIGN UP TODAY Stock Information Fortress Biotech, Inc. NASDAQ: FBIO Price/Change $2.980.02 (0.68%) Day Range 2.8701 - 3.00 52 Week Range 2.36 - 6.10 VIEW INVESTOR PRESENTATION VIEW INVESTOR RELATIONS Fortress Biotech programs include product candidates in development at Fortress, its majority-owned and majority-controlled partner companies and entities in which it holds minority ownership positions. © 2021 Fortress Biotech, Inc. All Rights Reserved. Facebook Twitter Linkedin Accessibility Statement Privacy Policy Disclaimer Sitemap Market Data copyright © 2021 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.